Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT
Geron Corporation (NASDAQ:GERN) is one of the
In other news, on January 12, Geron Corporation (NASDAQ:GERN) shared its financial guidance for 2026. The company expects RYTELO net product revenue to be between $220 million and $240 million. Total operating expenses are projected to range from $230 million to $240 million. Geron Corporation (NASDAQ:GERN) said its 2026 outlook reflects expected revenue growth along with a year-over-year reduction in operating expenses, which it believes supports the strength of its balance sheet.
For 2026, Geron Corporation (NASDAQ:GERN) said its main priorities include growing RYTELO commercially in the US, exploring opportunities to expand RYTELO into lower-risk myelodysplastic syndromes (LR-MDS) markets outside the US, and advancing its Phase 3 IMpactMF trial.
Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapies for patients with blood cancers.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Dell Rides An AI Wave: Analyst Cites $43 Billion Order Backlog
Plug Power Faces Federal Lawsuit Over DOE Loan Claims
Donaldson's Q2 Earnings Miss Estimates, Revenues Increase Y/Y

Archer Aviation Q4 Earnings Loom: What Should You Do Now?

